http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016009674-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be1ae1f965148e029f744bb55cf78832 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1b44dc872f3b547c196fda71085dfbc |
| publicationDate | 2016-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2016009674-A1 |
| titleOfInvention | Prototypical brain protective activity of tetrahydro-n-methyl-2,2-diphenyl-3-furanomethanamine (ae37met) |
| abstract | Tetrahydro-N-methyl-2,2-diphenyl-3-furanomethanamine (AE37Met) is a highly selective ligand of the extrasynaptic NMDA receptors, of the M2 muscarinic autoreceptors and of the sigma-1 (σ1) receptors, with prototypical brain, preventive and therapeutical, protective activity. This invention concerns the prototypical profile of AE37Met and its pharmaceutically acceptable salts, with cytoprotective activity, more specifically for brain glial cells and neurons, against the neuro-degenerative diseases (e.g. Alzheimer's, Huntington's and Parkinson's diseases, depression, brain ischemia/hypoxia, traumatic brain injury and epilepsy), by the highly selective antagonisms, exerced by AE37Met, on the extrasynaptic NMDA glutamatergic receptors [eNMDA(−)] and on the M2 muscarinic cholinergic autoreceptors [M2(−)], associated with a highly selective sigma-1 agonism [σ1(+)]. The above prototypical profile was observed only with AE37Met between the other family members (AE14, AE37 and their enantiomers). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-1009143-B |
| priorityDate | 2013-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.